Home » Stocks » MDWD

MediWound Ltd. (MDWD)

Stock Price: $4.11 USD -0.36 (-8.05%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 111.98M
Revenue (ttm) 23.17M
Net Income (ttm) -9.59M
Shares Out 27.24M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $4.11
Previous Close $4.47
Change ($) -0.36
Change (%) -8.05%
Day's Open 4.41
Day's Range 4.11 - 4.50
Day's Volume 163,152
52-Week Range 1.73 - 6.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MediWound (MDWD) delivered earnings and revenue surprises of 16.67% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

First Quarter Revenues of $5.8 Million, an Increase of 32% Year-over-Year

5 days ago - GlobeNewsWire

MediWound (NASDAQ:MDWD) releases its next round of earnings this Wednesday, May 05. Here is Benzinga's essential guide to MediWound's Q1 earnings report.

6 days ago - Benzinga

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and r...

2 weeks ago - GlobeNewsWire

Data Expected Second-Half 2021 Data Expected Second-Half 2021

2 weeks ago - GlobeNewsWire

Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time

1 month ago - GlobeNewsWire

YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and re...

2 months ago - GlobeNewsWire

MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Fourth Quarter Revenues of $6.7 Million - Up 23% and Full-Year 20 20 Revenues of $ 2 1.8 Million - Product Revenue Up 117%

2 months ago - GlobeNewsWire

Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021

2 months ago - GlobeNewsWire

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

2 months ago - GlobeNewsWire

YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

3 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALNA, ALRN, MBIO, MCHX, OBSV, RWLK
3 months ago - InvestorPlace

Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients

3 months ago - GlobeNewsWire

YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

4 months ago - GlobeNewsWire

MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a...

4 months ago - Seeking Alpha

Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021

4 months ago - GlobeNewsWire

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

4 months ago - GlobeNewsWire

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 2.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of MediWound (NASDAQ:MDWD) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share rose 36.36% over the past year to ($0.07), which beat the estimate of ($...

6 months ago - Benzinga

Total Third Quarter R evenues of $6.6 Million Increased 29 % Y ear-over- Y ear

6 months ago - GlobeNewsWire

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

6 months ago - GlobeNewsWire

Top-line Data is Expected in the Second Half of 2021 Top-line Data is Expected in the Second Half of 2021

6 months ago - GlobeNewsWire

Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing

6 months ago - GlobeNewsWire

YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in ...

7 months ago - GlobeNewsWire

MediWound: An Underfollowed Opportunity At A Discount

8 months ago - Seeking Alpha

YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in se...

8 months ago - GlobeNewsWire

YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedic...

Other stocks mentioned: VCEL
8 months ago - GlobeNewsWire

Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient Screening

9 months ago - GlobeNewsWire

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wou...

9 months ago - GlobeNewsWire

MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

YAVNE, Israel, June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn...

10 months ago - GlobeNewsWire

Mediwound, An Attractive Opportunity Through The Coronavirus Crisis

11 months ago - Seeking Alpha

Investors always look for companies with a high level of profitability regardless of the present market condition.

Other stocks mentioned: BWXT, ISDR, TNK
11 months ago - Zacks Investment Research

MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

MediWound (MDWD) delivered earnings and revenue surprises of 35.71% and 4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of MediWound (NASDAQ:MDWD) moved higher by 6% in pre-market trading after the company reported Q1 results.

11 months ago - Benzinga

EscharEx U.S. Phase 2 Study Resumed Patient Screening EscharEx U.S. Phase 2 Study Resumed Patient Screening

11 months ago - GlobeNewsWire

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

YAVNE, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn ...

1 year ago - GlobeNewsWire

Company Announces Appointments of Samuel Moed and David Fox Chairman Stephen T. Wills Named Executive Chairman Company Announces Appointments of Samuel Moed and David Fox Chairman Stephen T. Wills Named...

1 year ago - GlobeNewsWire

YAVNE, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in se...

1 year ago - GlobeNewsWire

Total non-dilutive funds for NexoBrid now valued at over $200 million Total non-dilutive funds for NexoBrid now valued at over $200 million

1 year ago - GlobeNewsWire

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological dr... [Read more...]

Industry
Biotechnology
IPO Date
Mar 20, 2014
CEO
Sharon Malka
Employees
75
Stock Exchange
NASDAQ
Ticker Symbol
MDWD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MediWound stock is "Strong Buy." The 12-month stock price forecast is 7.50, which is an increase of 82.48% from the latest price.

Price Target
$7.50
(82.48% upside)
Analyst Consensus: Strong Buy